Replies to post #198785 on Biotech Values

[DewDiligence]

I don't have an educated opinion on TBRA, although I try to stay abreast of what they're doing.

[DewDiligence]

TBRA -58% on phase-2b NASH data from CENTAUR trial:

http://finance.yahoo.com/news/tobira-therapeutics-announces-clinically-statistically-120000416.html

Although the study did not meet its primary endpoint of a two-point reduction in the NAFLD Activity Score, CENTAUR did demonstrate a clinically and statistically significant improvement in fibrosis of at least one stage without worsening of NASH, one of two key secondary endpoints, after only one year of treatment.